Advances in Neurocardiology: Focus on Anticoagulation for Valvular Heart Disease With and Without Atrial Fibrillation
- 1 December 2022
- journal article
- review article
- Published by Wolters Kluwer Health in Stroke
- Vol. 53 (12) , 3763-3768
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral ValveNew England Journal of Medicine, 2020
- Rivaroxaban Versus Warfarin in Patients with Mechanical Heart Valves: Open-Label, Proof-of-Concept trial—The RIWA studyAmerican Journal of Cardiovascular Drugs, 2020
- Overestimation of Stroke Risk in Rheumatic Mitral Stenosis and the Implications for Oral AnticoagulationCirculation, 2020
- A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve ReplacementNew England Journal of Medicine, 2020
- 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial FibrillationJACC, 2019
- Incidence and risk factors for thromboembolism and major bleeding in patients with mechanical valve prosthesis: A nationwide population-based studyAmerican Heart Journal, 2016
- Dabigatran Versus Warfarin After Bioprosthesis Valve Replacement for the Management of Atrial Fibrillation Postoperatively: DAWA Pilot StudyDrugs in R&D, 2016
- Clinical Outcomes at 1 Year Following Transcatheter Aortic Valve ReplacementJAMA, 2015
- Dabigatran versus Warfarin in Patients with Mechanical Heart ValvesNew England Journal of Medicine, 2013
- Late incidence and determinants of stroke after aortic and mitral valve replacementThe Annals of Thoracic Surgery, 2004